Subsequently, structural studies have allowed structure-based drug design of more selective and potent Tankyrase inhibitors with cytotoxic potential demonstrated in CRC cell lines [184,192], for instance, JW74 [193], JW55 [194], WIKI4 [195,196], K-756 [197], G007-LK [198,199], and NVP-TNKS656 [200]. The gene discussed is TNKS; the disease is colorectal carcinoma.